Wordt geladen...
Experience with degarelix in the treatment of prostate cancer
Degarelix is a gonadotrophin-releasing hormone (GnRH) antagonist for the first-line treatment of androgen-dependent advanced prostate cancer. It has a direct mechanism of action that blocks the action of GnRH on the pituitary with no initial surge in gonadotrophin or testosterone levels. Degarelix i...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3547532/ https://ncbi.nlm.nih.gov/pubmed/23372607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287212461048 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|